CF treatment helps sinus symptoms, weight after lung transplant

Study finds Trikafta 'can be safely incorporated' into post-transplant care

Written by Andrea Lobo, PhD |

A woman sits on an exam table talking to a nurse.

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) eased sinus symptoms and helped stabilize weight without evidence of worsening lung function in people with cystic fibrosis (CF) who had received a lung transplant, a study found.

The researchers said the findings show that Trikafta “can be safely incorporated into post–lung transplant care for selected [people with CF].”

The study, “Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy,” was published in the Journal of Cystic Fibrosis.

CF is caused by mutations in the CFTR gene that lead to no or faulty CFTR, a protein that regulates the movement of salt and water in and out of cells. When CFTR does not work properly, thick and sticky mucus accumulates in several organs, including the lungs, digestive system, and paranasal sinuses, the air-filled spaces in the face.

Trikafta is a CFTR modulator that helps faulty CFTR work more effectively. While benefits have been documented in lung function, respiratory symptoms, and nutritional health, less is understood about Trikafta in people with CF who underwent lung transplant, where its effects outside the lungs must be balanced with potential safety risks.

Recommended Reading
Banner image for Jennifer Cogliano's Living Beyond column on cystic fibrosis issues.

In life with CF and transplant, it’s important to find joy wherever we can

Analysis of medical records

Researchers in the U.S. analyzed medical records from 59 people with CF who underwent lung transplants and were followed at Brigham and Women’s Hospital/Boston Children’s Hospital between June 2019 and September 2025. Thirty participants received Trikafta for at least four weeks after lung transplant, while 29 did not receive the treatment. Eight participants died during the study period.

Participants’ average age at the end of the study or when they died was about 48, and 61% were women. Most had at least one copy of the F508 del mutation (89.8%). A mean of more than 14 years had passed since the last transplant. Trikafta treatment lasted a mean of 2.7 years.

Among 11 participants who completed a sinus symptom questionnaire (SNOT-22) before and after initiating treatment, 10 reported that their symptoms significantly eased on Trikafta. Five patients without questionnaire results also experienced improvements, based on a medical procedure to examine the inside of the nose and throat.

The study also examined changes in weight. Patients who received Trikafta for at least one month maintained their weight over the study period, in contrast to the decline seen in those who did not receive the treatment for that period.

Lung function remained broadly stable regardless of Trikafta use. Ten patients completed pharmacogenomic testing, broadly used to assess how genes affect response to medications, to inform tacrolimus dosing at Trikafta initiation. Tacrolimus is used to prevent immune system attacks against the transplanted organ. The researchers emphasized that pharmacogenomic testing does not replace monitoring of tacrolimus blood levels after initiating Trikafta.

The treatment was generally well tolerated. Two patients discontinued it due to gastrointestinal intolerance without sinus symptom easing.

“In this single center retrospective cohort analysis, we report sustained improvements in sinonasal disease and weight maintenance with preserved spirometric [lung function] values,” the scientists wrote.

“It is important to point out that although ours is one of the largest and longest studied cohorts published to date, the sample size allows for limited power to detect all differences that may be present,” they added. “Further work will expand to the broader CF [lung transplant] registry, further characterize extrapulmonary effects, and incorporate non-registry data … to better understand long-term outcomes in this population.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.